These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M. J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339 [Abstract] [Full Text] [Related]
3. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Haddad É, Barnes D, Kafal A. Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304 [Abstract] [Full Text] [Related]
4. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Stein MR, Koterba A, Rodden L, Berger M. Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101 [Abstract] [Full Text] [Related]
5. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531 [Abstract] [Full Text] [Related]
6. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease. Arora R, Newton TC, Nelson MR. Ann Allergy Asthma Immunol; 2007 Oct; 99(4):367-70. PubMed ID: 17941286 [Abstract] [Full Text] [Related]
9. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Berger M, Murphy E, Riley P, Bergman GE, VIRTUE Trial Investigators. South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467 [Abstract] [Full Text] [Related]
10. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M. J Microbiol Immunol Infect; 2006 Apr; 39(2):114-20. PubMed ID: 16604243 [Abstract] [Full Text] [Related]
12. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study Group. Clin Immunol; 2008 Jan; 126(1):81-8. PubMed ID: 17964220 [Abstract] [Full Text] [Related]
13. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Shapiro RS. Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460 [Abstract] [Full Text] [Related]
14. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Bayrakci B, Ersoy F, Sanal O, Kiliç S, Metin A, Tezcan I. Turk J Pediatr; 2005 Jul; 47(3):239-46. PubMed ID: 16250308 [Abstract] [Full Text] [Related]
15. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder. Sarı G, Güven Bilgin B, Yılmaz E, Aytac G, Edeer Karaca N, Aksu G, Kutukculer N. Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716 [Abstract] [Full Text] [Related]
16. Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy. Egawa M, Kanegane H, Imai K, Morio T, Miyasaka N. J Matern Fetal Neonatal Med; 2019 Sep; 32(18):3092-3096. PubMed ID: 29614902 [Abstract] [Full Text] [Related]
19. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy. Krishnarajah G, Lehmann JK, Ellman B, Bhak RH, DerSarkissian M, Leader D, Bullinger AL, Sheng Duh M. Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353 [Abstract] [Full Text] [Related]
20. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Clin Ther; 2014 Nov 01; 36(11):1616-24. PubMed ID: 25236916 [Abstract] [Full Text] [Related] Page: [Next] [New Search]